FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology and molecular genetics. There are disclosed the versions of disintegrin and their use in pharmacology. The version of disintegrin involves the recovered polypeptide which possesses αvβ3 receptor antagonist activity and substantially lower ability to block αIIbβ3 and/or α5β1 integrin receptor than wild-type disintegrin. The polypeptide is coded by a modified nucleotide sequence of disintegrin possessing lower ability to bind to αIIbβ3 and/or α5β1 integrin than wild-type disintegrin.
EFFECT: invention may be used for treating and/or preventing the αvβ3 integrin-associated diseases in a mammal, which include without limitation osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatoid arthritis, and osteoarthritis.
23 cl, 16 dwg, 1 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| αvβ3 INTEGRIN SELECTIVE POLYPEPTIDES CONJUGATED WITH VARIANT OF HUMAN SERUM ALBUMIN (HSA), AND THEIR PHARMACEUTICAL APPLICATIONS | 2010 |
|
RU2547592C2 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| INTEGRIN-TARGETING PROTEIN AND THE METHODS OF ITS USE | 2016 |
|
RU2806524C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| POLYPEPTIDE FOR INHIBITING MIGRATION AND INVASION OF PROSTATE CANCER | 2019 |
|
RU2711085C1 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| POLYPEPTIDE FOR INHIBITING MIGRATION AND INVASION OF SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY | 2018 |
|
RU2705547C1 |
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
